Approval adds to the treatment options for the more than 35 million adults in the U.S. affected by chronic kidney disease (CKD) Jardiance ® (empagliflozin) 10 mg tablets significantly reduced the risk ...
- More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. RIDGEFIELD, Conn. and INDIANAPOLIS, June 21, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has ...
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company announced the US Food and Drug Administration (FDA) approved Jardiance (empagliflozin) tablets as an adjunct to diet and ...
Please provide your email address to receive an email when new articles are posted on . Jardiance had a 28% relative risk reduction for kidney disease progression vs. placebo. The drug also showed a ...
RIDGEFIELD, Conn. and INDIANAPOLIS, May 23, 2014 -- The European Commission granted marketing authorization for Jardiance® (empagliflozin) tablets, a sodium glucose co-transporter 2 (SGLT2) inhibitor, ...
Both Farxiga (dapagliflozin) and Jardiance (empagliflozin) help manage blood sugar levels in adults and some children with type 2 diabetes. They also reduce risks associated with chronic kidney ...
RIDGEFIELD, Conn. and INDIANAPOLIS, March 8, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance ® (empagliflozin) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback